Cellectis bioresearch Announces Establishment of Subsidiary in the US
Cellectis bioresearch announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.
Eric Merle will serve as Sales Director US. His strong experience in the research tool area in the United States will be a valuable asset in the launch of Cellectis bioresearch Inc.’s operations. Eric Merle will be in charge of recruiting and managing a dedicated team, covering the entire US market. He will report to Luc Selig, VP Sales & Marketing at Cellectis bioresearch.
“Cellectis bioresearch’s goal is to make its genome customization products the gold standard for the life sciences community worldwide,” explains Luc Selig. “The opening of our American subsidiary will provide us with a presence in the largest global Life Science market and allow us to be closer to our clients to better meet their needs.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Nicholas_A._Cummings_(Nick_Cummings)
Mane_(horse)

Discovery of a Primordial Metabolism in Microbes
Category:Molluscicides
Proteins may point to alcohol use test
Brain inflammation targeted in first drug discovery project from £3m Dementia Consortium
Centre_for_Infectious_Disease_Research_in_Zambia_(CIDRZ)
Tiotropium
First open genetic testing accreditation workshop proves a major success - Participants from across Europe welcome initiative

New SARS-CoV-2 variant Eris on the rise - SARS-CoV-2 lineage EG.5.1 has an advantage at evading neutralizing antibodies
Leishman_stain
